| Number of patent applications |
7 in Korea
2 outside Korea
*These numbers include the number of unpublished patent applications |
| Number of registered patents |
7 in Korea
2 in USA
*These numbers include the number of unpublished patent applications |
| Registered patents |
2002-0027380 |
Method of B-LCL generation |
|
Tumor antigen protein, gene, or peptide form topoisomerase 2 alpha |
| 10-0468486 |
Dendritic cells transduced with recombinant adenovirus AdVCEA which generate CEA specific CLs, vaccine and pharmaceutical composition comprising the same |
| 10-0975820 |
Enhancement of proliferation and antigen presentation of human B cells in vitro by K562 cells expressing CD40L |
| 10-1079314 |
Efficient generation of survivin-specific cytotoxic T lymphocytes from healthy persons in vitro:quantitative and qualitative effects of CD4+ T cells |
| 2011-0035633 |
Selective addition of CXCR3+CCR4-CD4+ Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro |
| 7,364,743 |
Nucleotide sequence encoding PTD and CEA fusion protein, TAT-CEA fusion protein, anti-tumor vaccine and pharmaceutical composition for treating tumor comprision the fusion protein |
| 8,012,468 |
Dendrite cells transduced with recombinant adenovirus advcea which generate CEA-specific
cytotoxic T lymphocytes, vaccine and pharmaceutical composition comprising the same |
